UPDATE 2-Dutch pull Pfizer vaccine batch after infants die

AMSTERDAM, Nov 5 (Reuters) - Dutch authorities say they have banned use of a batch of Pfizer's Prevenar, or Prevnar, after three infants died within two weeks of receiving the anti-infection vaccination. "On average about 5 to 10 deaths are reported annually after babies get vaccines," said a spokeswoman for the Dutch health institute RIVM. "We now have three cases in a short period, that is unusual and the reason for suspending the batch." She said RIVM was investigating the cause of the infants' deaths. Other batches of Prevenar, known as Prevnar in the United States, will continue to be used. Pfizer spokeswoman Gwen Fisher said preliminary investigations by the company and health authorities had found no link between the vaccinations and the deaths. She said the company initiated the "quarantine" of the batch which she said contained 110,000 doses of Prevenar, used to prevent pneumonia and related infections. Fisher said the three infants also received two unrelated other vaccines as part of routine immunisations. No other Prevenar batches were suspended and infants in the Netherlands will continue to be vaccinated with it as part of routine immunisation, she added. A spokesman for the European Medicines Agency in London said its officials were working with the Dutch authorities to find out if there were any safety issues with the vaccine batch. The vaccine is one of the most widely used in the world and generated sales for U.S. drugmaker Wyeth of $2.7 billion in 2008. Wyeth, which has just been acquired by U.S. rival Pfizer , had asked for the suspension of batch D66977 of Prevenar, RIVM said in a statement. Officials at Pfizer in New York could not immediately be reached for comment. (Reporting by Gilbert Kreijger, Ben Hirschler in London and Ransdell Pierson in New York; editing by Simon Jessop and David Cowell) Keywords: DUTCH DEATHS/PFIZER ([e-mail]; [phone]; Reuters Messaging: [e-mail]) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.